{"id":"W2984201945","doi":"10.1093/eurheartj/ehz807","title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","year":2019,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Institutes of Health; Eisai; Idorsia Pharmaceuticals; British Heart Foundation; Osprey Medical; Daiichi-Sankyo; Medicines Company; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; US WorldMeds; Ionis Pharmaceuticals; Abbott Vascular; Medicure; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; ZonMw; Amgen; Pfizer","keywords":"Medicine; P2Y12; Pharmacodynamics; Pharmacokinetics; Placebo; Pharmacology; Antagonist; Platelet aggregation inhibitor; Platelet; Internal medicine; Anesthesia; Receptor; Platelet aggregation","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007398666,0.0005160929,0.001274451,0.0001588459,0.0001524584,0.0004288046,0.0002406571,0.0005839037,0.001342222],"category_scores_gemma":[0.001208425,0.0002732099,0.0005191809,0.0001553016,0.0005039421,0.0004564175,0.0001830633,0.001008715,0.0002562482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000297453,"about_ca_system_score_gemma":0.0003481971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002799333,"about_ca_topic_score_gemma":0.0006641925,"domain_scores_codex":[0.9995746,0.0001939634,0.00003754987,0.0000829032,0.00006910518,0.00004192116],"domain_scores_gemma":[0.9992555,0.0001819794,0.0003054052,0.00004134357,0.00003276618,0.0001829985],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6956888,0.01734402,0.05875371,0.0006982354,0.001516801,0.0003288806,0.0002672723,0.001590671,0.0975145,0.0001033503,0.0006797714,0.1255139],"study_design_scores_gemma":[0.1982509,0.6373492,0.1501666,0.00004445283,0.000840061,0.0006438441,0.0001236051,0.00304757,0.008371199,0.00009848785,0.001019328,0.00004471917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987606,0.0008282032,0.0001070817,0.00004303758,0.00001034049,0.00006192036,0.00004326177,0.000008767923,0.0001368183],"genre_scores_gemma":[0.9990196,0.0002922074,0.0002703412,0.00007639707,0.00004437749,0.00006631431,0.00008579475,0.000002150699,0.0001427365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001342222,"threshold_uncertainty_score":0.004490256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01332700713066531,"score_gpt":0.2480995130300835,"score_spread":0.2347725058994182,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}